NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [3] - The company is developing NRX-101, which has been designated as an investigational Breakthrough Therapy by the FDA for suicidal treatment-resistant bipolar depression and chronic pain [3] - NRx Pharmaceuticals plans to file a New Drug Application (NDA) for Accelerated Approval for NRX-101 targeting patients with bipolar depression and suicidality or akathisia [3] Recent Developments - NRx has initiated a New Drug Application filing for NRX-100 (IV ketamine) aimed at treating suicidal depression, based on results from well-controlled clinical trials and new data from French health authorities [4] - The company has received Fast Track Designation from the US FDA for the development of ketamine (NRX-100) to treat patients with acute suicidality [4] Upcoming Events - NRx Pharmaceuticals will release its fourth quarter and full year 2024 financial results on March 17, 2025, before the market opens [1] - A conference call will be held at 8:30am ET on the same day to discuss the financial results and provide a corporate update [1][2]